Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Jesse L. Cox

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4590-7381; OpenAlex author ID A5004120220, A5112102357. Sources: OpenAlex.

Their work

Papers
24 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
82
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: none · 2020: none · 2021: 1 paper · 2022: 7 papers · 2023: 2 papers · 2024: 5 papers · 2025: none · 2026: 6 papers

Papers 24

  1. NR4A2 induces perineural invasion in head and neck squamous cell carcinoma and pancreatic ductal adenocarcinoma via CXCL5/CXCR2 signaling axis. Co-author DOI 10.1016/j.canlet.2026.218269↗
  2. SLC22A3/OCT3 drives serotonin-mediated stemness in pancreatic cancer. Co-author DOI 10.1016/j.celrep.2026.117387↗
  3. Distinct glycosyltransferase expression governs organ-specific survival in pancreatic cancer metastasis. Co-author DOI 10.1038/s41388-026-03896-5↗
  4. Targeting Oncomucin-Driven Immunosuppression Improves the Efficacy of K-ras G12D Inhibition in Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2026.04.041↗
  5. Dietary Fat Content Influences PanIN Progression and Pancreatic Cancer Development in Mice. Co-author DOI 10.1158/2767-9764.crc-25-0777↗
  6. Combination Immunotherapy Enhances Serial Radiofrequency Ablation Induced Systemic Antitumor Immunity in Pancreatic Cancer Co-author DOI 10.64898/2026.04.05.713683↗
  7. Secretory Trefoil Factor 1 (TFF1) promotes gemcitabine resistance through chemokine receptor CXCR4 in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.canlet.2024.217097↗
  8. Single-cell RNA-sequencing of human spleens reveals an IDO-1+ tolerogenic dendritic cell subset in pancreatic cancer patients that is absent in normal individu… Co-author DOI 10.1016/j.canlet.2024.217321↗
  9. Connectivity mapping-based identification of pharmacological inhibitor targeting HDAC6 in aggressive pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41698-024-00562-5↗
  10. Cancer-Associated Fibroblast Induces Acinar-to-Ductal Cell Transdifferentiation and Pancreatic Cancer Initiation Via LAMA5/ITGA4 Axis. Co-author DOI 10.1053/j.gastro.2023.12.018↗
  11. PAF1/HIF1α axis rewires the glycolytic metabolism to fuel aggressiveness of pancreatic cancer. Co-author DOI 10.1186/s40170-024-00354-2↗
  12. Muc4 loss mitigates epidermal growth factor receptor activity essential for PDAC tumorigenesis. Co-author DOI 10.1038/s41388-022-02587-1↗
  13. A Novel HOXA10-Associated 5-Gene-Based Prognostic Signature for Stratification of Short-term Survivors of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-23-0825↗
  14. Endothelin-axis antagonism enhances tumor perfusion in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2022.215801↗
  15. Small molecule inhibitor against onco-mucins disrupts Src/FosL1 axis to enhance gemcitabine efficacy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2022.215922↗
  16. The GSK3 kinase and LZTR1 protein regulate the stability of Ras family proteins and the proliferation of pancreatic cancer cells. Co-author DOI 10.1016/j.neo.2022.01.002↗
  17. Reduction in O-glycome induces differentially glycosylated CD44 to promote stemness and metastasis in pancreatic cancer. Co-author DOI 10.1038/s41388-021-02047-2↗
  18. PAF1 cooperates with YAP1 in metaplastic ducts to promote pancreatic cancer. Co-author DOI 10.1038/s41419-022-05258-x↗
  19. Mucin 5AC Serves as the Nexus for β-Catenin/c-Myc Interplay to Promote Glutamine Dependency During Pancreatic Cancer Chemoresistance. Co-author DOI 10.1053/j.gastro.2021.09.017↗
  20. Mucin 5AC-Mediated CD44/ITGB1 Clustering Mobilizes Adipose-Derived Mesenchymal Stem Cells to Modulate Pancreatic Cancer Stromal Heterogeneity. First author DOI 10.1053/j.gastro.2022.02.032↗
  21. Secretory Mucin 5AC Promotes Neoplastic Progression by Augmenting KLF4-Mediated Pancreatic Cancer Cell Stemness. Co-author DOI 10.1158/0008-5472.can-20-1293↗
  22. Generation of tumorigenic porcine pancreatic ductal epithelial cells: toward a large animal model of pancreatic cancer First author DOI 10.1101/267112↗
  23. SOX2 functions as a molecular rheostat to control the growth, tumorigenicity and drug responses of pancreatic ductal adenocarcinoma cells. Co-author DOI 10.18632/oncotarget.8994↗
  24. Context-dependent function of the deubiquitinating enzyme USP9X in pancreatic ductal adenocarcinoma. Co-author DOI 10.4161/cbt.29182↗

Closest collaborators

The 25 strongest of 82 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Surinder K. Batra · 18 shared papers, 2021–2026 · strength 3.18
  2. Moorthy Palanimuthu Ponnusamy · 10 shared papers, 2021–2026 · strength 1.72
  3. Palanisamy Nallasamy · 9 shared papers, 2021–2026 · strength 1.56
  4. Sanchita Rauth · 9 shared papers, 2021–2026 · strength 1.52
  5. Pranita Atri · 7 shared papers, 2021–2026 · strength 1.17
  6. Zahraa Wajih Alsafwani · 5 shared papers, 2024–2026 · strength 1.08
  7. Ashu Shah · 6 shared papers, 2021–2026 · strength 1.02
  8. Koelina Ganguly · 6 shared papers, 2021–2026 · strength 1.00
  9. Sushil Kumar K · 6 shared papers, 2021–2024 · strength 0.85
  10. Saravanakumar Marimuthu · 4 shared papers, 2022–2026 · strength 0.80
  11. Rama Krishna Nimmakayala · 5 shared papers, 2022–2024 · strength 0.79
  12. Michael Anthony Hollingsworth · 6 shared papers, 2014–2026 · strength 0.77
  13. Satyanarayana Rachagani · 5 shared papers, 2021–2024 · strength 0.71
  14. Maneesh Jain · 4 shared papers, 2022–2024 · strength 0.63
  15. Parthasarathy Seshacharyulu · 4 shared papers, 2022–2024 · strength 0.62
  16. Lynette M. Smith · 4 shared papers, 2021–2024 · strength 0.60
  17. Subodh M. Lele · 3 shared papers, 2022–2026 · strength 0.58
  18. Venkatesh Varadharaj · 3 shared papers, 2022–2026 · strength 0.58
  19. Nivedeta Krishna Kumar · 3 shared papers, 2022–2026 · strength 0.58
  20. Paul M. Grandgenett · 3 shared papers, 2022–2026 · strength 0.57
  21. Frank Leon · 3 shared papers, 2022–2026 · strength 0.54
  22. Urvinder Kaur Sardarni · 2 shared papers, 2026 · strength 0.53
  23. Lincoln N. Strickland · 2 shared papers, 2026 · strength 0.53
  24. Jennifer M. Bailey · 2 shared papers, 2026 · strength 0.53
  25. Ayoola O. Ogunleye · 3 shared papers, 2022–2024 · strength 0.53

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.